drugset / Trial / NCT04325581
Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Investigators postulate that the metabolic effects of LSG would be augmented with the use of liraglutide leading to additional excess weight loss, improved glucose homeostasis, decreased intrapancreatic and intrahepatic fat than either of them individually. However there are no studies till date which have evaluated the combined effects of two modalities of weight loss on the above mentioned parameters. This study plans to compare the effects of liraglutide in post- LSG obese patients in a placebo controlled design.
Timeline
- Start
- 2016-08-01
- Primary completion
- 2018-12-31
- Completion
- 2018-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liraglutide | Peptide | 1.8 mg | Subcutaneous |
Indications
No indication recorded.